FROM BENCH TO BEDSIDE: TRANSLATING ADCS INTO THE CLINIC

Defining immune-active mechanisms of PDL1V in translational ADC development

Bioconjugate Insights 2026; 1(1), 1–5

DOI: 10.18609/bci.2026.001

Published: 19 January
Interview
Megan Atkins


“Our observation of synergistic antitumor activity at multiple nonclinical doses supports that PDL1V allows the functional activation and trafficking of PD-L1-positive cytotoxic immune cells within a wide therapeutic window.”

Lauren Coyle (Launch Commissioning Editor, Bioconjugate Insights) speaks with Megan Atkins (Senior Scientist, Translational Pharmacology, Pfizer) about advancing PDL1V from non-clinical characterization to pivotal trials, and how deeper immune profiling is reshaping the future of immune-active ADCs.



}